Pharma Pulse 5/17/24: AI & ML Through the Eyes of the FDA, Johnson & Johnson to Acquire Proteologix & more

US Pharma and Biotech Summit 2024: Artificial Intelligence and Machine Learning Through the Eyes of the FDA

In an interview with Pharm Exec Associate Editor Don Tracy, Tala Fakhouri, Associate Director for Policy Analysis, FDA, discusses the use of artificial intelligence and machine learning in drug development.

Advise Patients About Travel Vaccines

As summer approaches, many will be planning vacations and trips abroad

Apple Watch's afib-tracking app certified by FDA for use in clinical studies

The watch’s sensor and software marked the first digital health product to be qualified under the agency’s Medical Device Development Tools program—a voluntary pathway that deems certain technologies as reliable enough to be employed in scientific research without needing additional review.

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

Johnson & Johnson announced that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment.

Carta Healthcare on LinkedIn:

Thank you to Pharmaceutical Executive for engaging in a dialogue with our own Matt Hollingsworth about this crucial issue that is impacting nurses nationwide.

Moving forward, policymakers, employers, and healthcare stakeholders must continue to collaborate on sustainable solutions to address workforce challenges and ensure a robust healthcare system capable of meeting the needs of all patients. At Carta Healthcare, our solutions have revolutionized the processes surrounding registry databases, resulting in markedly faster data collection, superior quality of data, and considerable cost savings for healthcare providers.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs